Research and Markets: Cancer Symptoms Partnering Analysis 2009-2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/s7ddcd/cancer_symptoms) has announced the addition of the "Cancer Symptoms Partnering 2009-2014" report to their offering.

The Cancer Symptoms Partnering 2009-2014 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of cancer symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cancer symptoms technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report provides details of the latest cancer symptoms agreements announced in the healthcare sectors, covering:

  • Symptoms
  • Oral mucositis
  • Cancer pain
  • Bone
  • Neuropathic
  • Muscular
  • Lymphoedema
  • Alopecia
  • Cachexia
  • Ulcers
  • Dysphagia
  • Tiredness
  • Weight Loss
  • Nausea
  • Vomiting
  • Chemotherapy
  • Radiotherapy

This data driven report includes:

  • Trends in cancer symptoms dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 130 cancer symptoms contract documents
  • The leading cancer symptoms deals by value since 2009

In Cancer Symptoms Partnering 2009-2014, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in cancer symptoms partnering

Chapter 3 - Leading cancer symptoms deals

Chapter 4 - Dealmaking directory

Chapter 5 - Partnering resource center

Companies Mentioned

  • Abbott
  • Actavis
  • Actelion
  • Allergan
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • CSL
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • Galderma
  • Hospira
  • Johnson & Johnson
  • Merck & Co
  • Merck KGaA
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Purdue
  • Roche
  • Shire
  • Takeda
  • Teva
  • Watson

For more information visit http://www.researchandmarkets.com/research/s7ddcd/cancer_symptoms

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices